Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

19.87
+0.74003.87%
Post-market: 19.56-0.3100-1.56%19:53 EDT
Volume:2.13M
Turnover:43.18M
Market Cap:2.00B
PE:-4.34
High:20.81
Open:20.00
Low:19.85
Close:19.13
Loading ...

Press Release: Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Dow Jones
·
04 Dec 2024

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

Zacks
·
20 Nov 2024

Watch Out: 5 Altcoins in South Korea See Trading Volume Boom – Here’s the List

CoinMarketCap
·
18 Nov 2024

Daily Market Review: BTC, ETH, RAY, MATIC, BEAM

CoinMarketCap
·
09 Nov 2024

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink

TipRanks
·
07 Nov 2024

Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Nov 2024

Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data and Preclinical Achievements

Stock Track
·
07 Nov 2024

Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise

MT Newswires Live
·
07 Nov 2024

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Zacks
·
07 Nov 2024

RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating

MT Newswires Live
·
06 Nov 2024

Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data

Stock Track
·
06 Nov 2024

Scotiabank Remains a Hold on Beam Therapeutics (BEAM)

TIPRANKS
·
06 Nov 2024

Beam Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
06 Nov 2024

RBC Capital Remains a Hold on Beam Therapeutics (BEAM)

TIPRANKS
·
06 Nov 2024

Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data

Stock Track
·
06 Nov 2024

Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27

MT Newswires Live
·
06 Nov 2024

Beam Therapeutics Inc : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $39 From $27

THOMSON REUTERS
·
06 Nov 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ...

GuruFocus.com
·
06 Nov 2024

Q3 2024 Beam Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
06 Nov 2024

Beam Therapeutics Reports Steady Progress in Q3 2024

TIPRANKS
·
06 Nov 2024